세계의 PEG화 의약품 시장(-2035년) : 분자별(고분자 의약품, 저분자 의약품, 지질 나노입자 및 리포솜), 용도별, 유통 경로별, 지역별
Global PEGylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs, Small Molecular Drugs and Lipid Nanoparticles and Liposomes), by Application, by Distribution Channel and by Region Forecast till 2035
상품코드:1699225
리서치사:Market Research Future
발행일:2025년 02월
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
한글목차
PEG화 의약품 시장 규모는 예측 기간 동안 CAGR 5.17%로 큰 폭의 성장을 보일 것으로 예상됩니다.
PEG화는 공유결합 및 비공유결합 글리콜 폴리머 사슬을 펩타이드, 단백질, 항체 조각, 효소, 올리고뉴클레오티드와 같은 생리활성 분자에 결합시키는 것을 말합니다. 이는 임상 환경에서 약물의 치료 효과를 향상시키는 안전한 전략입니다. 치료 현장에서 사용되는 FDA 승인 PEG화 의약품은 다양한 종류가 있습니다.
만성질환의 유병률 증가, 생물학적 제제의 발전, 새로 승인된 PEG화 의약품이 세계 페그 인터페이스 시장을 주도하고 있습니다. 반면, 높은 제조 비용, 규제 장벽 및 잠재적인 부작용은 시장 성장을 제한하는 요인으로 작용하고 있습니다. 그러나 시장 확대, 새로운 약물전달 기술, 맞춤형 의료의 발전으로 인해 향후 시장 성장 가능성이 기대되고 있습니다.
지역별 분석
북미는 2024년에 가장 큰 시장 점유율을 차지했으며, 2035년에는 89억 6,941만 달러에 달할 것으로 예상됩니다. 한편, 아시아태평양은 예측 기간 동안 CAGR 7.03%로 가장 큰 성장을 보일 것으로 예상됩니다.
북미 시장에서는 미국과 캐나다가 우위를 보이고 있습니다. 암 등 만성질환의 증가가 시장 확대의 원동력이 되고 있습니다.
유럽 각국 정부의 만성질환 억제를 위한 지원과 투자가 유럽 지역 확대에 힘을 실어주고 있습니다.
세계의 PEG화 의약품 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추정과 예측, 각종 부문별·지역별·주요 국가별 분석, 경쟁 환경, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
성장 촉진요인
만성질환 발생률 증가
생물학의 진보
최근 승인된 PEG화 의약품
성장 억제요인
높은 생산 비용
규제상 장벽
잠재적 부작용
기회
신흥 시장
혁신적인 약물전달 시스템
맞춤형 의료
제5장 시장 요인 분석
Porter's Five Forces 분석
COVID-19가 세계의 PEG화 의약품 시장에 미치는 영향
항PEG 항체 정성 분석과 PEG화 의약품에 대한 영향
제6장 세계의 PEG화 의약품 시장 : 분자별
개요
고분자 의약품
단백질과 펩타이드
효소
압타머
저분자 의약품
지질 나노입자(LNP)와 리포솜
제7장 세계의 PEG화 의약품 시장 : 용도별
개요
종양
신경
자가면역질환
혈액
기타
제8장 세계의 PEG화 의약품 시장 : 유통 채널별
개요
병원 약국
온라인 약국
소매 약국
제9장 세계의 PEG화 의약품 시장 : 지역별
개요
북미
미국
캐나다
유럽
독일
프랑스
영국
이탈리아
스페인
기타
아시아태평양
중국
인도
일본
호주
한국
기타
기타 지역
중동 및 아프리카
남미
제10장 경쟁 구도
시장 점유율 분석
경쟁 대시보드
공개 기업 주식 개요
비교 분석 : 주요 기업 재무 동향
주요 전개와 성장 전략
제11장 기업 개요
AMGEN INC.
PFIZER INC.
BIOGEN
BAYER AG
TAKEDA PHARMACEUTICAL COMPANY LIMITED
NOVO NORDISK A/S
SANDOZ GROUP AG
ASTRAZENECA
COHERUS BIOSCIENCES, INC.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON INC.
ALNYLAM PHARMACEUTICALS, INC.
LES LABORATOIRES SERVIER
제12장 데이터 인용
ksm
영문 목차
영문목차
Global PEGylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs, Small Molecular Drugs and Lipid Nanoparticles (LNP) and Liposomes), by Application (Oncology, Neurology, Autoimmune Diseases, Haematology and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) Forecast till 2035
Market Overview
The PEGylated Drugs Market is expected to grow at a substantial CAGR of 5.17% during the review period. Pegylation is the process of binding covalent and non-covalent glycol polymer chains to bioactive molecules such as peptides, proteins, antibody fragments, enzymes, and oligonucleotides. It is a safe strategy for improving the therapeutic efficacy of drugs in a clinical environment. There are various FDA-approved pegylated medicines used in therapeutic settings.
The growing prevalence of chronic diseases, advances in biologics, and newly approved pegylated pharmaceuticals are driving the worldwide pegylated market. Furthermore, high production costs, regulatory barriers, and potential adverse effects are limiting considerations for the market. However, expanding markets, novel medication delivery technologies, and customized medicine will give future market growth prospects.
The research includes a full overview of the pegylated antibody's benefits, market growth, driving forces, and challenges. It also sheds information on the leading key players' contributions and developments in the PEGylated Proteins Market.
The primary driving force behind the growth of the PEGylated Drugs Market is the rising prevalence of diseases such as cancer, the advancement of biologics sectors, and the expansion of pharmaceutical businesses worldwide. Furthermore, the rising incidence of chronic illnesses and cancer-related deaths in Canada will contribute to the expansion of pegylated pharmaceuticals in the market.
Market Segment Overview
The PEGylated Drugs Market is divided into three segments: molecule, indication, and region.
The Market is divided into three segments based on molecule: macromolecular drugs, small molecular drugs, and lipid nanoparticles (LNP) and liposomes.
The global pegylated pharmaceuticals market is divided into five applications: oncology, neurology, autoimmune diseases, haematology, and others.
The market is divided into three segments based on distribution channel: hospital pharmacies, retail pharmacies, and online pharmacies.
Regional analysis
The Global PEGylated Drugs Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America held the greatest market share in 2024 and is expected to reach USD 8,969.41 million by 2035. However, Asia-Pacific is expected to develop at the fastest CAGR of 7.03% over the projection period.
The American market is separated into two regions: North and South America. The United States and Canada are the dominant regions in the North American market. The increased prevalence of chronic diseases, such as cancer, is driving market expansion.
The European government's assistance and investment in lowering chronic diseases is fueling the expansion of the regional market. The European continent is further divided into Western Europe and Eastern Europe. Western Europe is also divided into the United Kingdom, Italy, France, Spain, and the rest of Western Europe.
Major players.
Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Biogen, BioMarin Pharmaceutical Inc, Coherus BioSciences, Enzon, and Leadiant Biosciences, Inc. are among the companies operating in the PEGylated Drugs Market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES
4.2.2 ADVANCEMENTS IN BIOLOGICS
4.2.3 RECENTLY APPROVED PEGYLATED DRUGS
4.3 RESTRAINTS
4.3.1 HIGH PRODUCTION COSTS
4.3.2 REGULATORY HURDLES
4.3.3 POTENTIAL SIDE EFFECTS
4.4 OPPORTUNITY
4.4.1 EMERGING MARKETS
4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS
4.4.3 PERSONALIZED MEDICINE
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET
5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS 50
6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE
6.1 OVERVIEW
6.2 MACROMOLECULAR DRUGS
6.2.1 PROTEIN AND PEPTIDE
6.2.2 ENZYME
6.2.3 APTAMER
6.3 SMALL MOLECULAR DRUGS
6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES
7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 ONCOLOGY
7.3 NEUROLOGY
7.4 AUTOIMMUNE DISEASES
7.5 HAEMATOLOGY
7.6 OTHERS
8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL
8.1 OVERVIEW
8.2 HOSPITAL PHARMACY
8.3 ONLINE PHARMACY
8.4 RETAIL PHARMACY
9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 AUSTRALIA
9.4.5 SOUTH KOREA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST & AFRICA
9.5.2 SOUTH AMERICA
9.5.2.1 BRAZIL
9.5.2.2 MEXICO
9.5.2.3 ARGENTINA
9.5.2.4 REST OF SOUTH AMERICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2024
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT APPROVAL
10.6.2 PRODUCT EXPANSION
10.6.3 APPROVAL DENIED
10.6.4 PRODUCT DISCONTINUATION
10.6.5 AGREEMENT/ACQUISITION
10.6.6 CLINICAL TRIAL FINDINGS
11 COMPANY PROFILES
11.1 AMGEN INC.
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 PFIZER INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 BIOGEN
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 BAYER AG
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGY
11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCT OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 NOVO NORDISK A/S
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 SANDOZ GROUP AG
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 ASTRAZENECA
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 COHERUS BIOSCIENCES, INC.
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 F. HOFFMANN-LA ROCHE LTD.
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.10.6 KEY STRATEGIES
11.11 JOHNSON & JOHNSON INC.
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 SWOT ANALYSIS
11.11.6 KEY STRATEGIES
11.12 ALNYLAM PHARMACEUTICALS, INC.
11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL OVERVIEW
11.12.3 PRODUCTS OFFERED
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIES
11.13 LES LABORATOIRES SERVIER
11.13.1 COMPANY OVERVIEW
11.13.2 FINANCIAL OVERVIEW
11.13.3 PRODUCT OFFERED
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIES
12 DATA CITATIONS
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
